The overexpression of the Fms-like receptor tyrosine kinase-3 (FLT-3) in MLL-r leukemia, which results in the constitutive activation of FLT-3 signaling, could provide an opportunity for therapeutic targeting [82]. The gene discussed is KMT2A; the disease is leukemia.